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Background:  It is  well  known  that left  atrial  appendage  (LAA)  dysfunction  plays  an  important  role  in  the
occurrence  of  cardioembolic  stroke.  The  atrium  is  the  main  source  of  brain  natriuretic  peptide  (BNP)  in
patients  with  atrial ﬁbrillation  (AF).  We  hypothesized  that  the  plasma  BNP  level  would  be  a sensitive
predictor  of  LAA  dysfunction  in  patients  with  acute  ischemic  stroke.
Methods  and  results:  Transesophageal  echocardiography  was  performed  and  plasma  BNP  levels  were
measured  in  223  patients  (145  males,  age  69  ±  14  years),  within  7  days  after  the  onset  of  acute  ischemic
stroke.  None  of  the  patients  had  a  history  of  congestive  heart  failure.  LAA  thrombus  was  detected  in  23
of 77  (30%)  patients  with  AF.  Plasma  BNP  levels  were  markedly  higher  in  patients  with  cardioembolic
stroke  compared  to  those  without  (144  pg/ml  vs. 35  pg/ml,  p <  0.05).  Plasma  BNP  levels were  signiﬁcantly
correlated  with  LAA  emptying  ﬂow  velocity  regardless  of  sinus  rhythm  (R  =  −0.352) or AF  (R =  −0.436).
Furthermore,  among  patients  with  cardioembolic  stroke,  plasma  BNP  levels  were  markedly  higher  in
patients with  cardiogenic  stroke,  as  diagnosed  by transesophageal  echocardiography,  than  in  those  with
cryptogenic  stroke  (193  pg/ml  vs. 14  pg/ml,  p < 0.05).  Multivariate  logistic  regression  analysis  showed  that
a BNP  concentration  >90  pg/ml  was  an  independent  predictor  of  cardiogenic  stroke  (odds  ratio  41.39, 95%
conﬁdence  interval  1.28–138;  p = 0.0358).
Conclusion:  Elevated  plasma  BNP  concentrations  may  be  a  reliable  surrogate  marker  for  the  prediction  of
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The National Institute of Neurological Disorders and Stroke
NINDS) has characterized cardioembolic stroke as an important
linical issue, because it is the most common cause of death in
atients with acute ischemic stroke [1,2]. It is well known that the
eft atrial appendage (LAA) is a major source of thromboembolism
n stroke patients with atrial ﬁbrillation (AF) [3–6]. Many clinical
tudies have shown a close relationship between LAA thrombus
ormation and left atrial mechanical remodeling, based on ﬁndings
rom transesophageal echocardiography (TEE) [7,8]. It was  reported
hat the presence of spontaneous echocardiographic contrast (SEC)
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or measurement of LAA peak ﬂow velocity (LAA eV) by TEE is useful
for the detection of LAA dysfunction, which causes LAA thrombus
formation [9,10].  However, TEE is a semi-invasive procedure and
therefore cannot be used as a screening tool to quantify the risk of
stroke in patients with AF.
Brain natriuretic peptide (BNP) levels increase in patients with
heart disease [11–13],  and it has been used as a marker that is
produced by the heart. Plasma BNP is frequently elevated after
acute ischemic stroke [14,15] and it has been shown to be an
independent predictor of mortality in stroke patients [16]. Many
studies have demonstrated that BNP is secreted mainly from the
ventricular myocardium [17]. However, it was  also reported that
the left atrium is the main source of BNP in patients with AF
[13]. Recent reports have suggested an association between plasma
BNP levels and cardioembolic stroke [18,19].  However, it is not
known whether plasma BNP levels are associated with LAA func-
tion as evaluated by TEE. We  hypothesized that elevated BNP levels
are associated with LAA dysfunction, which causes LAA thrombus
vier Ltd. All rights reserved.
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ormation in patients with acute ischemic stroke. In the present
tudy, plasma BNP levels were compared with conventional mark-
rs of LAA dysfunction, and the feasibility of plasma BNP level as a
redictor of LAA dysfunction and cardioembolic stroke in patients
ith acute ischemic stroke was investigated.
ethods
tudy patients
Transthoracic echocardiography (TTE) and TEE were performed
n 223 consecutive patients referred to our department of neuro-
urgery for the treatment of acute cerebral infarction from April
005 to January 2010. TTE and TEE were performed within 7
6 ± 1) days of onset. The following patients were excluded: those
ith structural heart diseases such as ischemic cardiomyopathy
n = 9), dilated cardiomyopathy (n = 4), hypertrophic cardiomyopa-
hy (n = 2), or valvular heart disease (n = 8), and those in whom
EE failed (n = 3). We  deﬁned ischemic cardiomyopathy as hav-
ng prior myocardial infarction and left ventricular wall motion
synergy. Assessment at admission included determination of the
isk factors for cerebral infarction, the clinical ischemic stroke cat-
gory (NINDS) [20], and disease severity, as assessed using the US
ational Institute of Health Stroke Scale (NIHSS) [1].  Patients with
o history of AF and no documented AF on continuous electrocardo-
raphic (ECG) monitoring during hospitalization were categorized
s patients with sinus rhythm. Patients with a history of AF prior to
dmission and/or documented AF on continuous ECG monitoring
uring hospitalization were categorized as patients with chronic
F.
According to NINDS clinical categories, the ﬁndings of computed
omography, magnetic resonance imaging, and TEE, patients were
ategorized into two groups based on the incidence of cardioem-
olic stroke (non-cardioembolic stroke: n = 154, mean age 67 ± 14
ears; cardioembolic stroke: n = 69, mean age 72 ± 13 years). Since
ardioembolic stroke includes cardiogenic and cryptogenic stroke,
e further divided patients with cardioembolic stroke into those
ith cardiogenic stroke and those with cryptogenic stroke based on
he TEE ﬁndings. Patients with cardiogenic stroke were deﬁned as
hose in whom intracardiac thrombi and/or severe LAA dysfunction
severe or moderate SEC and/or LAA eV < 20 cm/s) were detected by
EE (n = 51). Patients with cryptogenic stroke were deﬁned as those
n whom normal LAA function and atrial septal aneurysm (ASA)
nd/or patent foramen ovale (PFO) were detected by TEE (n = 18).
atient characteristics, echocardiographic parameters, and plasma
NP levels were compared between non-cardioembolic stroke and
ardioembolic stroke. The study protocol was approved by the local
thics committee, and all subjects gave informed consent.
chocardiography
TTE was performed on a Hewlett Packard SONOS 7500 ultra-
ound instrument (Hewlett Packard, Palo Alto, CA, USA), equipped
ith a sector transducer. A 5 MHz  phased-array multiplane probe
as used for TEE. The following parameters were assessed using
tandard views and techniques [21]: left atrial dimension (LAD),
eft ventricular end-diastolic dimension (LVDd), left ventricular
ercent fractional shortening (LVFS), the ratio of peak early to
ate ﬁlling velocity (E/A), deceleration time of early diastolic ﬁll-
ng (DCT), and the ratio of peak early mitral annular velocity to
 wave (E/E′) as measured by TTE. The tissue Doppler velocities
ere measured at the lateral annulus by using spectral Doppler
issue imaging. The severity of SEC was deﬁned according to
he criteria of Fatkin et al., and was graded from 0 to 4+, with
rades 3+ and 4+ being deﬁned as SEC [22]. ASA was  deﬁned asiology 60 (2012) 126–132 127
protrusion of the septum, or a portion of it, at least 10 mm into the
left or right atrium [23]. PFO was  assessed at rest and during the Val-
salva maneuver, with intravenous injection of agitated saline. PFO
was diagnosed when at least four microbubbles passed through the
septum into the left atrium, either spontaneously or during the Val-
salva maneuver [24]. LAA thrombus was  diagnosed when a ﬁxed or
mobile echogenic mass could be clearly differentiated from the wall
of the left atrium or atrial appendage. LAA eV was  measured using
pulsed wave Doppler, with the sample volume placed 1 cm distal
from the mouth of the appendage by TEE. Peak ﬂow velocity within
each RR interval was obtained by scanning the appendage at angles
between 0◦ and 90◦ [25]. In patients with AF, echocardiographic
measurements were obtained as the mean of ﬁve consecutive car-
diac cycles, and in patients with sinus rhythm, as the mean of three
consecutive cardiac cycles. All ﬁndings were evaluated by two inde-
pendent experienced echo-cardiologists, who were blinded to the
clinical and other details of the patients. We deﬁned LAA dysfunc-
tion as LAA eV < 20 cm/s and/or which was  the severity of SEC grade
3+ or 4+ [9,22].
Hemostatic markers
Venous blood samples were collected at the time of the echocar-
diographic studies for determination of plasma BNP levels and
serum hemostatic marker levels. Plasma BNP levels were mea-
sured using a commercially available speciﬁc radioimmunoassay
(Shiono RIA BNP assay kit, Shionogi Co. Ltd., Tokyo, Japan) [26].
Other parameters were measured by routine laboratory methods.
Statistical analysis
Results are expressed as mean ± standard deviation (SD) for
continuous variables and as percentages of the total number of
patients for categorical variables. Skewed variables are presented
as medians with interquartile range. Statistical analyses were per-
formed using StatView, version 5.0 (SAS Institute Inc., Cary, NC,
USA). t-tests and chi-square tests were used for comparison of con-
tinuous and categorical variables, respectively. If data were not
normally distributed, the Mann–Whitney U test was used. Com-
parisons among three or more groups were performed by analysis
of variance (ANOVA) with the Bonferroni post hoc test. p-Values
<0.05 were considered signiﬁcant. A receiver operating character-
istic (ROC) curve was  constructed to determine the relevant plasma
BNP cut-off value giving optimum sensitivity and speciﬁcity for pre-
dicting cardiogenic stroke. The area under the curve was calculated
by the trapezoidal rule. Logistic regression analysis was performed
to identify independent predictors of the prevalence of cardiogenic
stroke among all patients. Variables that were signiﬁcant by uni-
variate logistic regression analysis (p < 0.05) were entered into the
multivariate analysis.
Results
The clinical characteristics of the patients with or without
cardioembolic stroke are compared in Table 1. Patients with car-
dioembolic stroke were signiﬁcantly older, had higher heart rates,
and higher CHADS2 scores. The prevalence of AF was  higher
in patients with cardioembolic stroke than in those with non-
cardioembolic stroke. Patients with cardioembolic stroke had a
signiﬁcantly larger LAD, larger LVDd, smaller LVFS, larger E/A (mea-
sured in patients with sinus rhythm), larger E/E′, and a smaller LAA
eV compared to those without. The prevalence of LAA thrombus
and SEC was  signiﬁcantly greater in patients with cardioembolic
stroke than in those without. Plasma BNP was signiﬁcantly higher
in patients with cardioembolic stroke than in those without. Fur-
thermore, among patients with cardioembolic stroke, plasma BNP
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Table 1
Comparison of clinical characteristics between patients with and without cardioembolic stroke.
Non-cardioembolic (n = 154) Cardioembolic (n = 69) p-Value
Age (years) 67 ± 14 72 ± 13 0.0065
Gender (M/F) 104/50 41/28 0.2403
Heart  rate (bpm) 69 ± 13 78 ± 16 <0.0001
Atrial ﬁbrillation 29 (19%) 48 (70%) <0.0001
Hypertension 113 (73%) 48 (70%) 0.5570
Diabetes mellitus 44 (29%) 19 (28%) 0.8739
Hyperlipidemia 87 (56%) 19 (28%) <0.0001
Current smoking 90 (58%) 33 (48%) 0.1406
Previous stroke 43 (27%) 18 (27%) 0.5992
NIHSS 4.6 ± 5.2 5.1 ± 5.9 0.5328
CHADS2 score 1.4 ± 1.0 1.9 ± 1.3 0.0012
Medication
Antiplatelets 90 (58%) 22 (31%) 0.0105
Anticoagulants 15 (10%) 25 (36%) <0.0001
PT-INR 1.59 ± 0.51 1.68 ± 0.53 0.5964
Echocardiography
LAD  (mm)  37 ± 6 43 ± 6 <0.0001
LVDd (mm) 47  ± 5 48 ± 6 0.0444
LVFS (%) 36 ± 7 33 ± 8 0.0005
LAA  eV (cm/s) 53 ± 22 30 ± 27 <0.0001
SEC  6 (4%) 34 (49%) <0.0001
LAA  thrombus 0 (0%) 27 (39%) <0.0001
E/A  (sinus rhythm) 0.84 ± 0.34 1.05 ± 0.51 0.0073
Deceleration time 206 ± 48 199 ± 91 0.3865
E/E′ 7.5 ± 2.4 9.7 ± 4.8 0.0041
Aortic plaque 35 (22%) 3 (5%) 0.0172
Carotid plaque 34 (22%) 7 (11%) 0.0518
Blood  marker
BNP (pg/ml) 35 (13–85) 144 (61–274) <0.0001
Fibrinogen (mg/dl) 395 ± 132 485 ± 193 <0.0001
D-dimer (mg/ml) 1.0 (0.5–2.8) 2.0 (0.7–3.5) 0.0196
FDP  (mg/ml) 3.8 (2.8–6.0) 4.8 (3.5–7.9) 0.0065
Date are expressed as mean ± SD, as number (percentage), or as median (interquartile range). NIHSS, National Institutes of Health Stroke Scale; CHADS2, an acronym for
Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack; PT-INR, prothrombin time-international normalized ratio;
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vAD,  left atrial dimension; LVDd, left ventricular end-diastolic dimension; LVFS, lef
elocity  at atrial systole; SEC, spontaneous echo contrast; E/A, the ratio of peak ea
ortic  plaque, protruding >5 mm and/or mobile plaques in the aortic arch; Carotid
nternal carotid artery; BNP, brain natriuretic peptide; FDP, ﬁbrinogen degradation
evels were signiﬁcantly higher in patients with cardiogenic stroke
han in those with cryptogenic stroke (Fig. 1).
The patients were classiﬁed into three groups based on LAA eV
nd the prevalence of LAA thrombus. Patients with LAA throm-
us had signiﬁcantly higher BNP levels compared to those without
AA thrombus (Fig. 2A). Despite the absence of LAA thrombus,
ig. 1. Comparison of plasma brain natriuretic peptide (BNP) levels among patients
ith non-cardioembolic, cryptogenic, and cardiogenic stroke. *p < 0.01 versus non-
ardioembolic stroke; †p < 0.01 versus cryptogenic stroke. ANOVA, analysis of
ariance.ricular percent fractional shortening; LAA eV, left atrial appendage emptying ﬂow
late ﬁlling velocity; E/E′ , the ratio of peak early mitral annular velocity to E wave;
ue, protruding plaque with 50% luminal stenosis in the common and/or proximal
cts.
patients with low LAA eV had higher BNP levels compared to
those with high LAA eV (Fig. 2A). Irrespective of cardiac rhythm,
plasma BNP levels were higher in patients with LAA throm-
bus than in those without LAA thrombus (Fig. 2B). Plasma BNP
levels were signiﬁcantly correlated with LAA eV regardless of
their cardiac rhythm (Fig. 3A,B). Even in 88 patients with pre-
served LV systolic (LVFS >35%) and diastolic function (E/E′ < 10),
plasma BNP levels were signiﬁcantly correlated with LAA eV
(R = 0.325, p < 0.05).
The optimum plasma BNP cut-off value for predicting cardio-
genic stroke (cardioembolic stroke excluding cryptogenic stroke)
was determined as that which gave the greatest sum of sen-
sitivity plus speciﬁcity on the ROC curve. The ROC curve for
plasma BNP as a predictor for cardiogenic stroke is shown in
Fig. 4. The area under the ROC curve (AUC) was 0.892. For
a BNP level >90 pg/ml the sensitivity was 85% and the speci-
ﬁcity was 78%. Therefore, we  determined that the cut-off value
of BNP for predicting cardiogenic stroke is 90 pg/ml. As shown
in Fig. 5, patients with high BNP level had high prevalence
of LAA thrombus independently of CHADS2 score. No patients
with CHADS2 score <2 and BNP ≤ 90 pg/ml had LAA throm-
bus.
The incidence of AF and cardioembolic stroke, and CHADS2
scores were signiﬁcantly higher in patients with high BNP levels
(>90 pg/ml) than in those with low BNP levels (Table 2). Patients
with high BNP levels had a signiﬁcantly larger LAD, smaller LVFS,
higher E/A, higher E/E′, and lower LAA eV compared to those with
low BNP levels. Patients with high BNP levels had a signiﬁcantly
higher prevalence of SEC and LAA thrombus compared to those
with low BNP levels.
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Fig. 2. (A) Comparison of plasma BNP levels among patients with high LAA eV, low
LAA  eV, and LAA thrombus. *p < 0.01 versus LAA eV ≥ 20 cm/s; †p < 0.01 versus LAA
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cal stretching of the LV myocardium. In the present study, patients
with high plasma BNP levels had a higher E/E′ and left atrial volume
index and smaller LVFS compared to those with low plasma BNPV ≤ 20 cm/s. (B) Comparison of plasma BNP levels between patients with or with-
ut LAA thrombus. AF, atrial ﬁbrillation; ANOVA, analysis of variance; BNP, brain
atriuretic peptide; LAA eV, left atrial appendage emptying ﬂow velocity.
Logistic regression analysis was performed to identify indepen-
ent predictors of cardiogenic stroke (Table 3). In the univariate
ogistic regression analysis, age, CHADS2 score, LAD, LVFS, LAA
V, E/A, E/E′, ﬁbrinogen, BNP >90 pg/ml, and the presence of AF,
yperlipidemia, SEC, and LAA thrombus were signiﬁcantly associ-
ted with cardiogenic stroke. In the multivariate logistic regression
nalysis, the presence of AF and BNP >90 pg/ml was  independent
redictor of cardiogenic stroke (Table 3).
iscussion
It was reported that the left atrium is the main source of BNP
n patients with AF [13]. Ari et al. reported that plasma BNP was
seful as a predictor of the recurrence of AF after cardioversion
nd maintenance of sinus rhythm [27]. The present study showed
hat there was a signiﬁcant correlation between plasma BNP levels
nd parameters of LAA function such as LAA eV. Furthermore, the
OC curve demonstrated that plasma BNP showed good sensitivity
nd speciﬁcity for predicting cardiogenic stroke. We  determined
hat the cut-off value of BNP for predicting cardiogenic stroke is
0 pg/ml. We  are convinced that this cut-off value may  become the
oninvasive diagnostic tool for cardiogenic stroke, and that it is use-
ul to decide initiating early anticoagulant therapy for cardiogenic
troke without waiting for TEE ﬁndings.Fig. 3. Relationship between plasma BNP level and LAA eV in patients with sinus
rhythm (A) and atrial ﬁbrillation (B). BNP, brain natriuretic peptide; LAA eV, left
atrial appendage emptying ﬂow velocity.
The present study showed that plasma BNP levels were associ-
ated with LAA function, independently of cardiac rhythm (Fig. 3).
BNP is secreted into the plasma mainly in response to mechani-Fig. 4. The ROC curve analysis for plasma BNP as a predictor of cardiogenic stroke.
AUC, area under the curve; ROC, receiver operating characteristic; BNP, brain natri-
uretic peptide.
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retic peptide; LAA, left atrial appendage.
evels. These results suggest that BNP is secreted by both LA and LV
yocardium. The LA is exposed to high LV ﬁlling pressures caused
y LV systolic and diastolic dysfunction, and the long-term increase
n LV ﬁlling pressure leads to LA dilatation and LAA dysfunction.
n the present study, even in patients with preserved LV systolic
able 2
omparison of clinical characteristics between patients with high BNP and low BNP.
BNP ≤90 pg/ml (n = 143)
Age (years) 66 ± 14 
Gender  (M/F) 93/50 
Heart  rate (bpm) 71 ± 14 
Atrial  ﬁbrillation 25 (17%) 
Hypertension 98 (69%) 
Diabetes mellitus 37 (26%) 
Hyperlipidemia 77 (54%)
Current smoking 81 (57%) 
Previous stroke 38 (27%) 
NIHSS  4.4 ± 5.0 
CHADS2 score 1.4 ± 1.0 
NINDS  clinical categories 
Cardioembolic stroke 21 (15%) 
Atherothrombotic stroke 54 (38%)
Lacunar stroke 27 (19%) 
Others or Undetermined 41 (29%) 
Medication
Anti  platelets 79 (55%) 
Anti  coagulants 18 (13%) 
PT-INR  1.63 ± 0.46 
Echocardiography
LAD  (mm)  37 ± 6 
LVDd  (mm)  47 ± 5 
LVFS  (%) 37 ± 6 
LAA  eV (cm/s) 54 ± 24 
SEC  10 (7%) 
LAA  thrombus 3 (2%) 
E/A  (sinus rhythm) 0.83 ± 0.33 
Deceleration time 210 ± 47 
E/E′ 7.1 ± 2.4 
Aortic  plaque 24 (17%) 
Carotid  plaque 31 (22%) 
Blood  marker
BNP (pg/ml) 26 (10–51) 
Fibrinogen (mg/dl) 388 ± 129 
D-dimer (mg/ml) 0.8 (0.5–2.5) 
FDP  (mg/ml) 3.8 (2.7–5.7) 
NP, brain natriuretic peptide; NIHSS, National Institutes of Health Stroke Scale; CHADS2,
nd  prior Stroke or transient ischemic attack; PT-INR, prothrombin time-international 
imension; LVFS, left ventricular percent fractional shortening; LAA eV, left atrial append
he  ratio of peak early to late ﬁlling velocity; E/E′ , the ratio of peak early mitral annular 
ortic  arch; Carotid plaque, protruding plaque with 50% luminal stenosis in the common iology 60 (2012) 126–132
and diastolic function, plasma BNP levels were signiﬁcantly corre-
lated with LAA eV. This result suggests that high BNP levels may
reﬂect the potential LAA dysfunction and preserved LV systolic and
diastolic function.
Patients with high CHADS2 score have been shown to have a
high incidence of ischemic stroke, despite receiving warfarin [28].
The present study demonstrated that patients with high BNP levels
had higher prevalence of LAA thrombus independently of CHADS2
score compared to those with low BNP levels (Fig. 5). This result
suggested that plasma BNP levels provide important additional
information for LAA dysfunction and/or LAA thrombus formation.
Further, BNP levels could successfully differentiate cardiogenic
stroke from cryptogenic stroke (Fig. 1). It is well known that cryp-
togenic stroke occurs mainly due to deep venous thrombus in
patients with ASA and/or PFO [29]. These results suggest that ele-
vated plasma BNP levels are associated with LAA dysfunction rather
than the presence of thrombus itself. Some previous studies have
shown a relationship between plasma BNP levels and cardioem-
bolic stroke. Shibazaki et al. reported that elevated plasma BNP
(>140 pg/ml) was a useful marker for the diagnosis of cardioem-
bolic stroke in patients with acute ischemic stroke [18]. However,
they did not elucidate the mechanism by which BNP was  increasedportion of patients with cardioembolic stroke enrolled in that study
(41%) was greater than in the present study (21%), the cut-off val-
ues for plasma BNP were higher in that study. Di Angelantonio et al.
BNP >90 pg/ml (n = 80) p-Value
73 ± 12 0.0003
52/28 0.9700
74 ± 17 0.1606
53 (66%) <0.0001
63 (79%) 0.1023
26 (35%) 0.2918
29 (36%) 0.0116
42 (53%) 0.5507
23 (29%) 0.7477
5.5 ± 6.1 0.1501
1.9 ± 1.2 0.0001
<0.0001
48 (60%)
16 (20%)
4 (8%)
12 (15%)
33 (41%) 0.0955
22 (28%) 0.0054
1.66 ± 0.58 0.8603
42 ± 6 <0.0001
48 ± 6 0.6207
33 ± 8 <0.0001
32 ± 21 <0.0001
30 (38%) <0.0001
24 (30%) <0.0001
1.02 ± 0.48 0.0063
195 ± 86 0.0961
10.2 ± 4.4 <0.0001
14 (18%) 0.2138
10 (13%) 0.0897
172 (115–269) <0.0001
485 ± 185 <0.0001
2.0 (0.8–4.3) 0.0005
4.8 (3.4–8.5) 0.0021
 an acronym for Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus,
normalized ratio; LAD, left atrial dimension; LVDd, left ventricular end-diastolic
age emptying ﬂow velocity at atrial systole; SEC, spontaneous echo contrast; E/A,
velocity to E wave; Aortic plaque, protruding >5 mm and/or mobile plaques in the
and/or proximal internal carotid artery; FDP, ﬁbrinogen degradation products.
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Table  3
Univariate and multivariate logistic regression analyses for cardiogenic stroke.
Variables Risk ratio 95% CI p-value
Univariate analysis
Age (per 1 year increase) 1.073 1.033–1.155 0.0003
Atrial  ﬁbrillation 60.97 17.77–209.2 <0.0001
Hyperlipidemia 0.206 0.096–0.443 <0.0001
CHADS2 score (per 1 SD increase) 1.610 1.610–2.232 0.0042
LAD  (mm) (per 1 SD increase) 7.020 3.797–12.96 <0.0001
LVFS  (%) (per 1 SD decrease) 1.905 1.350–2.674 <0.0001
LAA  eV (cm/s) (per 1SD decrease) 15.14 6.835–33.47 <0.0001
SEC 33.96 13.47–85.67 <0.0001
LAA  thrombus 51.33 14.34–183.7 <0.0001
E/A (per 1SD increase) 3.342 1.768–6.317 0.0002
E/E′ (per 1SD increase) 2.716 1.354–5.556 0.0062
Fibrinogen (mg/dl) (per 1 SD increase) 2.232 1.619–3.606 0.0042
BNP  >90 pg/ml 21.19 8.727–51.45 <0.0001
Multivariate analysis
Age (per 1 year increase) 0.949 0.799–1.126 0.5482
Atrial  ﬁbrillation 47.18 1.789–1244 0.0210
CHADS2 score (per 1 SD increase) 0.631 0.168–2.372 0.4960
LAD  (mm) (per 1 SD increase) 1.924 0.213–17.40 0.5599
LVFS  (%) (per 1 SD decrease) 1.474 0.566–3.842 0.4264
LAA  eV (cm/s) (per 1SD decrease) 4.955 0.609–39.77 0.1320
E/E′ (per 1SD increase) 1.099 0.126–9.599 0.9319
Fibrinogen (mg/dl) (per 1 SD increase) 3.074 0.851–12.87 0.1011
BNP  >90 pg/ml 41.39 1.280–1338 0.0358
95% CI, 95 percent conﬁdence interval. CHADS2, an acronym for Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic
a FS, le
ﬂ  early 
B
r
w
o
l
p
a
n
n
a
s
t
t
p
d
e
i
i
w
i
s
b
f
d
l
a
s
i
o
A
C
a
[ttack;  LAD, left atrial dimension; LVDd, left ventricular end-diastolic dimension; LV
ow  velocity at atrial systole; SEC, spontaneous echo contrast; E/A, the ratio of peak
NP,  brain natriuretic peptide.
eported that plasma BNP was correlated with LA/LAA dysfunction,
hich was evaluated by TEE in 48 patients with ischemic stroke
r transient ischemic attacks (TIA) [30]. Although the study popu-
ation was small, their results are consistent with those from the
resent study. Recently, Yukiiri et al. reported that plasma BNP was
 surrogate marker for differentiating cardioembolic stroke from
on-cardioembolic stroke. They also suggested that LAA eV was
ot a statistically signiﬁcant predictor of cardioembolic stroke after
djusting for AF, plasma BNP and LA diameter [19]. However, these
tudies did not distinguish between cardiogenic stroke and cryp-
ogenic stroke, which have completely different mechanisms of
hromboembolism. The present results clearly demonstrated that
lasma BNP levels were signiﬁcantly higher in patients with car-
iogenic stroke than in those with cryptogenic stroke. Therefore
levated plasma BNP levels may  be a promising marker for detect-
ng LAA dysfunction and thrombus formation in patients with acute
schemic stroke.
This study had several limitations. First, the number of patients
as relatively small. Second, the patients in this study were receiv-
ng low-dose anticoagulation therapy. However, there were no
igniﬁcant differences in BNP, LAA eV, and the prevalence of SEC
etween patients with and without the therapeutic range of war-
arin. Third, since we did not perform right heart catheterization
uring acute phase of stroke, it is possible that the patients showing
ow E/E′ included those with LV diastolic dysfunction.
In conclusion, high plasma BNP levels (>90 pg/ml) may  be a reli-
ble biomarker for LAA dysfunction, and may  predict cardiogenic
troke but not cryptogenic stroke. Plasma BNP may  be a useful non-
nvasive marker, in addition to the CHADS2 score, for stratiﬁcation
f the risk of cardioembolic stroke.
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